🔬 The Coolest Diffusion Research Isn't in LLMs — Evan Feinberg & Sergey Edunov, Genesis Molecular AI

AI-driven drug discovery focuses on overcoming the historical limitations of modeling protein-small molecule interactions. By shifting from generative adversarial networks to diffusion-based primitives, researchers achieve the sub-angstrom resolution necessary to accurately predict binding affinities and molecular structures. This precision is critical because drug discovery functions as a science of resolution, where even minor errors in atomic positioning render models ineffective for medicinal chemistry. Integrating physics-based priors with synthetic data and iterative reinforcement learning allows for more robust, generalizable models. Furthermore, the convergence of AI research with high-fidelity wet lab data—facilitated by partnerships with organizations like Insights—enables rapid design-make-test-analyze cycles. These advancements, coupled with agentic platforms, allow for continuous, automated drug discovery, effectively moving beyond static structure prediction toward actionable, therapeutic design that significantly accelerates the development of new medicines.